Hans-jurgen J. Wester

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 263 publications

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

Journal: British journal of pharmacology
Published: December 29, 2025

[99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family.

[99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 16, 2025

First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.

First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.

Journal: Nuklearmedizin. Nuclear medicine
Published: September 05, 2025

Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors.

Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors.

Journal: European journal of nuclear medicine and molecular imaging
Published: May 14, 2025

Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands.

Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands.

Journal: EJNMMI research
Published: March 10, 2025

Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer.

Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer.

Journal: Clinical nuclear medicine
Published: August 02, 2024

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

Journal: EJNMMI radiopharmacy and chemistry
Published: January 18, 2024

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

Journal: British journal of pharmacology
Published: December 20, 2023

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.

Journal: EJNMMI research
Published: December 04, 2023

Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.

Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 11, 2023

CCK2 Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga]Ga-DOTA-CCK-66.

CCK2 Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga]Ga-DOTA-CCK-66.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 17, 2023

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer.

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer.

Journal: EJNMMI research
Published: July 14, 2023
Showing 1-12 of 263

Last Updated: 09/26/2026